Since serum vascular endothelial growth factor–D (VEGF-D) has been used as the only non-invasive diagnostic biomarker for LAM [10], the incidence of lung biopsies in patients with LAM has declined rapidly. This evidence concerns the gene VEGFD and lymphangioleiomyomatosis.